EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Tevagrastim

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
N/0093	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	12/07/2023		PL	
IAIN/0090	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer	04/07/2023	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	responsible for importation and/or batch release - Not including batch control/testing				
IB/0089/G	This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	22/05/2023		SmPC, Labelling and PL	
IAIN/0088/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	06/03/2023		Annex II and PL	
IB/0087	B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	09/01/2023	n/a		

IB/0086/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	16/11/2022	n/a		
PSUSA/1391/202109	Periodic Safety Update EU Single assessment - filgrastim	05/05/2022	n/a		PRAC Recommendation - maintenance
N/0084	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/12/2021	04/04/2022	PL	
IB/0083	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	17/11/2021	n/a		
IA/0082/G	This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or	08/09/2021	n/a		

	intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
IB/0081	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	04/08/2021	n/a		
IA/0080/G	This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	04/05/2021	n/a		

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
IB/0079/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	13/04/2021	n/a		
WS/1974	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update section 6.4 of the SmPC in order to add finished product in-use storage conditions at room temperature not above 25 °C for a single period of up to 4 days. The package leaflet is updated accordingly. The MAH took also the opportunity to update the results for all filgrastim finished product long-term stability studies, which were presented in the dossier as `on-going', with results from the completed studies. The obtained results support the approved filgrastim drug product shelf-life of 30 months. The MAH also took the opportunity to correct some typos and formatting in line with the latest QRD template 10.1 and to update the list of local reps in the PL.	25/03/2021	04/04/2022	SmPC, Annex II, Labelling and PL	The PI is updated to reflect the change in the finished product in-use storage conditions at room temperature not above 25 °C for a single period of up to 4 days. The SmPC section 6.4 has been updated as follows: Within its shelf-life and for ambulatory use, the product may be removed from the refrigerator (2 °C – 8 °C) and stored at a temperature up to 25 °C for one single period of up to 4 days. If not used within 4 days, the product may be returned to the refrigerator (2 °C – 8 °C) up to the expiry date. Dispose of syringes if stored above 8 °C for more than 4 days. The PL has been updated accordingly.

	B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol				
II/0077	Submission of a variation to update the RMP to remove the additional pharmacovigilance activity "Cooperation with SCNIR (Severe Chronic Neutropenia International Registry) and analysis of corresponding Ratiograstim/Tevagrastim-SCNIR data". C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	01/10/2020	n/a		Considering that there is no safety signal for increased risk of immunogenicity, the cooperation with the Severe Chronic Neutropenia International Registry and analysis of corresponding Ratiograstim/Tevagrastim-SCNIR data are not needed anymore. Routine pharmacovigilance is considered adequate.
IB/0076	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	17/07/2020	n/a		
IA/0075	A.7 - Administrative change - Deletion of manufacturing sites	26/06/2020	n/a		
IA/0074/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder	17/04/2020	n/a		

	or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
IB/0073	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	07/01/2020	n/a		
IA/0072/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	18/12/2019	18/06/2020	Annex II	
IA/0071/G	This was an application for a group of variations.	13/08/2019	n/a		

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other				

	variation				
IB/0068	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	21/06/2019	18/06/2020	SmPC and PL	
IB/0070	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	06/06/2019	n/a		
PSUSA/1391/201809	Periodic Safety Update EU Single assessment - filgrastim	16/05/2019	n/a		PRAC Recommendation - maintenance
IB/0067/G	This was an application for a group of variations. B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the	29/03/2019	n/a		

	dossier) - Deletion of a supplier				
IAIN/0065	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	31/05/2018	13/05/2019	SmPC, Labelling and PL	
II/0064	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	28/09/2017	n/a		
II/0063/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	06/07/2017	n/a		
II/0061	B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change	10/11/2016	n/a		

	requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study				
IAIN/0062	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/10/2016	n/a		
IB/0060	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	26/09/2016	n/a		
IB/0059/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	08/06/2016	n/a		
PSUSA/1391/201509	Periodic Safety Update EU Single assessment - filgrastim	13/05/2016	n/a		PRAC Recommendation - maintenance
IAIN/0058	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/05/2016	n/a		
II/0055/G	This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters	07/04/2016	n/a		

	and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.e - Stability of FP - Change to an approved stability protocol				
IB/0057	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	18/03/2016	n/a		
N/0056	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/02/2016	13/05/2019	PL	
IA/0054	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	15/12/2015	n/a		
II/0052	B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method	05/11/2015	n/a		
IB/0051/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	30/01/2015	n/a		

	Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.f.1.e - Stability of FP - Change to an approved stability protocol				
IA/0050	A.7 - Administrative change - Deletion of manufacturing sites	03/10/2014	n/a		
IB/0049	B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	29/08/2014	n/a		
IA/0048/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test	15/08/2014	n/a		
IB/0047	B.I.c.1.z - Change in immediate packaging of the AS - Other variation	21/07/2014	n/a		

IB/0046	B.I.c.z - Container closure system of the AS - Other variation	28/05/2014	n/a		
IB/0045	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	20/05/2014	n/a		
IA/0044/G	This was an application for a group of variations. B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	12/03/2014	n/a		
IB/0043	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	24/01/2014	n/a		
IB/0042/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished	17/12/2013	n/a		

	product - Other changes to a test procedure (including replacement or addition)				
IA/0041/G	This was an application for a group of variations. B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	22/11/2013	n/a		
IB/0039	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by	30/10/2013	04/12/2014	SmPC and PL	Update of sections 4.4 and 4.8 of the SmPC to include a new adverse reaction, capillary leak syndrome, and a related warning following the same update for the originator. The PL is updated accordingly.

	the MAH. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IA/0040	B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits	21/10/2013	n/a		
R/0036	Renewal of the marketing authorisation.	30/05/2013	19/07/2013	SmPC, Annex II, Labelling and PL	
IA/0038/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test	11/07/2013	n/a		
IA/0037	B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits	11/04/2013	n/a		
IB/0035/G	This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits	18/01/2013	n/a		

	applied during the manufacture of the finished product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits				
II/0033/G	This was an application for a group of variations. To introduce a new site for WCB manufacture. To introduce a new WCB lot and some modifications to the manufacturing process of the WCB (change in scale, harvesting time and freezing volume). B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol	15/11/2012	n/a		
IB/0034	C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH	24/10/2012	31/10/2012	SmPC, Annex II, Labelling and PL	
IB/0030/G	This was an application for a group of variations.	21/09/2012	n/a		

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation				
IA/0032	A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	12/09/2012	n/a		
IB/0031	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation	10/09/2012	n/a		
II/0029	Replacement of the peptide mapping method. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS	19/07/2012	19/07/2012		
IB/0027	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	10/05/2012	n/a		
IA/0026/G	This was an application for a group of variations.	14/03/2012	n/a		

	B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
N/0024	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/12/2011	06/02/2012	PL	
IB/0025	B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)	08/12/2011	n/a		
IA/0022/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction	25/10/2011	n/a		
II/0021/G	This was an application for a group of variations.	20/10/2011	20/10/2011		

	Introduction of additional sterile filtration steps in the manufacturing process for the active substance. In addition, new in-process tests and limits are introduced. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits				
IA/0023	A.1 - Administrative change - Change in the name and/or address of the MAH	20/10/2011	n/a	SmPC, Annex II, Labelling and PL	
IB/0020/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	20/07/2011	n/a		
IB/0019	B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation	11/05/2011	n/a		
IB/0018/G	This was an application for a group of variations. C.I.3.a - Implementation of change(s) requested	21/02/2011	n/a	SmPC and PL	To implement changes requested in the PSUR 3 Assessment Report (dated 06 August 2010), as well as to bring the Product Information in line with the SmPC of the

	following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH				reference product (Neupogen). Minor linguistic amendments are introduced in the Package Leaflet for the following languages: ES, HU, IT, LT, NL, PL, SL . In addition, the MAH amended the European Medicines Agency web address in section 10 of the SmPC.
IA/0017	A.1 - Administrative change - Change in the name and/or address of the MAH	05/11/2010	n/a	SmPC, Labelling and PL	
IA/0016	To add an alternative site responsible for secondary packaging. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	29/09/2010	n/a		
IB/0014	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	27/08/2010	n/a		
IA/0015	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	13/08/2010	n/a		
II/0011	Addition an alternative site for manufacture (formulation, filling) of drug product.	24/06/2010	01/07/2010		

	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products.				
IB/0013	To change a test procedure for the active substance B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	20/05/2010	n/a		
IB/0012	To change a test procedure for the finished product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	20/05/2010	n/a		
II/0004	Extension of the finished product shelf-life from 24 to 30 months. Change(s) to shelf-life or storage conditions	19/11/2009	21/12/2009	SmPC, Labelling and PL	
IA/0010	IA_28_Change in any part of primary packaging material not in contact with finished product	02/10/2009	02/10/2009	SmPC, Labelling and PL	
IA/0009	IA_28_Change in any part of primary packaging material not in contact with finished product	02/10/2009	02/10/2009	SmPC, Labelling and	

				PL	
IA/0008	IA_28_Change in any part of primary packaging material not in contact with finished product	02/10/2009	02/10/2009	SmPC, Labelling and PL	
IA/0007	IA_28_Change in any part of primary packaging material not in contact with finished product	02/10/2009	02/10/2009	SmPC, Labelling and PL	
IA/0006	IA_28_Change in any part of primary packaging material not in contact with finished product	02/10/2009	02/10/2009	SmPC, Labelling and PL	
IA/0005	IA_28_Change in any part of primary packaging material not in contact with finished product	02/10/2009	02/10/2009	SmPC, Labelling and PL	
IA/0002	IA_01_Change in the name and/or address of the marketing authorisation holder	08/09/2009	n/a	SmPC, Labelling and PL	
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/02/2009	n/a	PL	